Market Data
Market Cap₹758.71 Cr.
52W High₹360
Current Price₹217.15
52W Low₹162
Down from 52W High39.7 %
Face Value₹10
Performance
ROCE34.89 %
ROE80.7 %
EPS (TTM)₹4.12
EPS Prev Qtr₹6.18
EPS Last Year₹2.44
EBITDA Qtr₹20.8 Cr.
Book Value₹15
Financial Health
Debt/Equity3.25
Debt/Profit4.03
Total Assets₹413.917 Cr.
Promoter Holding43.02 %
Earning Power17.96 %
Valuation
Stock P/E16.55
Industry P/E33.3
Price to Book14.24
Price to Sales1.2
Graham Number₹67.09
Key Metrics
Face Value
₹10
About Wanbury Ltd
Healthcare · Pharmaceuticals
Wanbury Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹758.71 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company demonstrates a strong ROCE of 34.89%, indicating efficient use of capital.
- ROE is exceptionally high at 80.7%, reflecting strong profitability relative to shareholder equity.
- The company has a solid promoter holding of 43.02%, suggesting confidence from insiders.
Weaknesses
- The company carries a relatively high debt to equity ratio of 3.25, indicating significant leverage.
- The P/B ratio of 15.87 suggests that the market values the company at a premium compared to its book value.
- The P/E ratio of 18.44 may indicate that the stock is relatively expensive compared to earnings.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | |
|---|---|---|---|---|
| Sales | 161.19 | 133.45 | 172 | 163.18 |
| ↳ QoQ Growth | - | -17.2% | +28.9% | -5.1% |
| Expenses | 144.51 | 122.83 | 145.75 | 142.39 |
| Operating Profit | 16.68 | 10.62 | 26.25 | 20.8 |
| OPM % | 10.35% | 7.96% | 15.26% | 12.75% |
| Other Income | 1.63 | 0.84 | 1.84 | 0.35 |
| Interest | 10.15 | 10.17 | 9.04 | 7.54 |
| Depreciation | 3.32 | 3.32 | 3.37 | 3.64 |
| EBITDA | 20 | 13.94 | 29.62 | 24.44 |
| EBITDA Margin % | 12.41% | 10.45% | 17.22% | 14.98% |
| Profit Before Tax | 8.17 | 1.29 | 19.05 | 13.61 |
| Tax % | 1.84% | 5.43% | -6.3% | 0.88% |
| Net Profit | 8.02 | 1.22 | 20.26 | 13.49 |
| ↳ QoQ Growth | - | -84.8% | +1560.7% | -33.4% |
| EPS | 2.44 | 0.38 | 6.18 | 4.12 |
Balance Sheet
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 32.75 | 32.7705 |
| Reserves | -4.8 | 20.5013 |
| Borrowings | 116.48 | 173.23 |
| Other Liabilities | 199.06 | 187.42 |
| Total Liabilities | 343.49 | 413.9172 |
| Fixed Assets | 166.56 | 200.6042 |
| CWIP | 3.01 | 5.3815 |
| Investments | 0.03 | 0.15 |
| Other Assets | 173.89 | 207.78 |
| Total Assets | 343.49 | 413.9172 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 26.1016 |
| Cash from Investing Activity | -51.1744 |
| Cash from Financing Activity | 25.7332 |
| Net Cash Flow | 0.6604 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 43.09% | 43.07% | 43.02% | 43.02% |
| FIIs % | 0.82% | 0.72% | 0.59% | 0.89% |
| DIIs % | 0% | 0% | 0% | 0.06% |
| Public % | 41.19% | 41.28% | 42.17% | 41.91% |
| No. of Shareholders | 17,717 | 17,261 | 16,732 | 17,174 |
Major Shareholders (>1%)
- Expert Chemicals (india) Pvt LtdPromoter and Promoter Group34.36%
- Kingsbury Investments IncPromoter and Promoter Group8.65%
- Suresh BhatiaPublic Shareholding3.11%
- Authum Investment And Infrastructure LimitedPublic Shareholding2.07%
As of 2026-06-30View all shareholders →